NCT07150715View on ClinicalTrials.gov

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2031

Conditions
Oligometastatic Prostate AdenocarcinomaRecurrent Prostate Adenocarcinoma
Interventions
DRUG

Actinium Ac 225 Vipivotide Tetraxetan

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Gallium Ga 68 Gozetotide

Given IV

DRUG

Lutetium Lu 177 Vipivotide Tetraxetan

Given IV

PROCEDURE

PSMA PET-CT Scan

Undergo PSMA PET/CT scan

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER